DOCSLIB.ORG

A Bioethics Tool for the Implementation of Global Principles by the Pharmaceutical Industry Daniel J

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Duquesne University Duquesne Scholarship Collection Electronic Theses and Dissertations Fall 1-1-2017 A Bioethics Tool for the Implementation of Global Principles by the Pharmaceutical Industry Daniel J. Hurst Duquesne University Follow this and additional works at: https://dsc.duq.edu/etd Part of the Bioethics and Medical Ethics Commons Recommended Citation Hurst, D. J. (2017). A Bioethics Tool for the Implementation of Global Principles by the Pharmaceutical Industry (Doctoral dissertation, Duquesne University). Retrieved from https://dsc.duq.edu/etd/193 This One-year Embargo is brought to you for free and open access by Duquesne Scholarship Collection. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of Duquesne Scholarship Collection. For more information, please contact [email protected]. A BIOETHICS TOOL FOR THE IMPLEMENTATION OF GLOBAL PRINCIPLES BY THE PHARMACEUTICAL INDUSTRY A Dissertation Submitted to the McAnulty College and Graduate School of Liberal Arts Duquesne University In partial fulfillment of the requirements for the degree of Doctor of Philosophy By Daniel J. Hurst, ThM, MDiv December 2017 Copyright by Daniel J. Hurst 2017 A BIOETHICS TOOL FOR THE IMPLEMENTATION OF GLOBAL PRINCIPLES BY THE PHARMACEUTICAL INDUSTRY By Daniel J. Hurst Approved August 31, 2017 ________________________________ ________________________________ Henk ten Have, MD, PhD Gerard Magill, PhD Director, Center for Healthcare Ethics The Vernon F. Gallagher Chair Professor of Healthcare Ethics Professor of Healthcare Ethics (Committee Chair) (Committee Member) ________________________________ ________________________________ Joris Gielen, PhD Henk ten Have, MD, PhD Assistant Professor of Healthcare Ethics Assistant Professor of History (Committee Member) Director, Center for Healthcare Ethics Professor of Healthcare Ethics ________________________________ James Swindal, PhD Dean, McAnulty College and Graduate School of Liberal Arts iii ABSTRACT A BIOETHICS TOOL FOR THE IMPLEMENTATION OF GLOBAL PRINCIPLES BY THE PHARMACEUTICAL INDUSTRY By Daniel J. Hurst December 2017 Dissertation supervised by Henk ten Have, MD, PhD Due to scandals of scientific misconduct, a climate of mistrust of science exists amongst the general public. This becomes of concern when we acknowledge that it is difficult for science and technology to flourish without broad societal trust. The pharmaceutical industry has often felt the brunt of such mistrust and has suffered many reputational setbacks over the past several years. Such reputational decline has a strong moral dimension, as it stems from issues such as the questionable conduct of clinical trials, pricing schemas, and access to medicines for low- or middle-income countries. The end product of such issues is the public not viewing pharmaceutical and biotechnology companies favorably. Since pharmaceutical and biotechnology companies are intrinsically tied to health and human flourishing, an ethical framework to aid in resolving both the ethical issues facing the industry and the resulting iv reputation it yields on both the industry as a whole and individual companies, could certainly be valuable. The central supposition of this dissertation is that additional work needs to be done in the area of pharmaceutical ethics and corporate social responsibility. Currently, no specifically global bioethics tool exists to implement ethics principles into the business practices of pharmaceutical and biotechnology companies, which constitutes a glaring gap in the implementation of ethics principles. This dissertation thus aims to do the following: (i) clarify the ethical grounding of pharmaceutical corporate social responsibility, and (ii) develop a global bioethics tool that can be utilized by the pharmaceutical industry as a manner to aid in implementing global ethics principles. The global bioethics tool seeks to implement a global ethical framework on the basis of performance indicators and best practices, with a long-term goal of helping society regain its trust in the pharmaceutical industry. While there are numerous bioethical guidelines available, it is argued that the UNESCO Universal Declaration on Bioethics and Human Rights, as a global ethics document with the backing of the global community, can be utilized to create such a tool by which to measure the ethical practices of pharmaceutical and biotechnology companies. v DEDICATION To my bride, Rachel. Your constant love, encouragement, and selflessness knows no bounds. And our son, Justus. May you exemplify your name. vi ACKNOWLEDGEMENT I would like to begin by thanking my dissertation director, Dr. Henk ten Have. You have believed in this project, and me, since its inception. You provided me with opportunities and insights that I will remember for a lifetime. Thank you for your mentorship, and in many ways, friendship. Your love of global bioethics is now deeply shared by me. Because of you, my thinking has been shaped in ways that I can only begin to understand. Dr. Lise Holst, you tried to get the global bioethics tool off the ground. We share the vision of what pharmaceutical bioethics and corporate social responsibility could be, and I hope one day that will be realized. Thank you for giving this project a fighting chance. Thanks also to Dr. Joris Gielen and Dr. Gerard Magill. Dr. Gielen, you provided me with numerous opportunities during the two years I worked for you that I would never have had otherwise. My qualitative research interests were spurred because of you. Rachel and I talk often and fondly about our trip to Leuven. Thank you for letting us be part of it. Dr. Magill, you challenged me to think deeply and provocatively. You always showed great interest in my work. Thank you for your guidance. To Glory, you constantly pour yourself out for the sake of the Center and its students. Countless times I came to you for answers, and you were always there. You celebrated with Rachel and I in the good times, and cried with us in the tough. Your friendship has been cherished. Mom and Dad, thank you for always supporting me to follow my interests, my academic pursuits, and instilling in me many of the values this work hopes to express. You have supported Rachel and I in countless ways along this journey. And finally, words fail to express the gratitude I have for my beautiful bride, Rachel. Your encouragement throughout this degree has sustained me. You have unconditionally stood by me and allowed me to chase my dreams. Being your husband is the joy of a lifetime. It is not hyperbole to say that this work would scarcely have been possible without the above people, as well as numerous others I have failed to mention. These words offer only a glimpse of your role. My sentiments echo those of Sebastian towards his friend Antonio in Shakespeare’s Twelfth Night, which I first read in an undergraduate course nearly a decade ago: I can no other answer make but thanks, And thanks; and ever thanks. (Act III, Scene 3) Soli Deo Gloria vii TABLE OF CONTENTS Page Abstract .......................................................................................................................................... iv Dedication ...................................................................................................................................... vi Acknowledgement ........................................................................................................................ vii Chapter 1: Introduction ....................................................................................................................1 Chapter 2: Global Bioethics and Human Rights ............................................................................34 2.1: Global Bioethics .........................................................................................................34 2.2: Human Rights .............................................................................................................53 2.3: Symbiotic Relationship ...............................................................................................67 Chapter 3: Corporate Social Responsibility and the Pharmaceutical and Biotechnology Industry ...........................................................................................................87 3.1: Social Responsibility in Global Health and Bioethics ................................................87 3.2: CSR and the Pharmaceutical and Biotechnology Industry ......................................100 Chapter 4: Analysis of Current Bioethics Guidelines ..................................................................140 4.1: Ethics Guidelines: 1947—Present ............................................................................140 4.2: UNESCO Universal Declaration on Bioethics and Human Rights ..........................160 4.3: Bioethics Governance and the Differing Models of Accreditation, Certification, and Rating ...............................................................................................................................169 Chapter 5: Global Bioethics Tool: Methodology and the Development of Indicators ................193 5.1: Rationale, Methodology, and Benchmarking ...........................................................194 5.2: Development of Indicators ........................................................................................211 Chapter 6: Global Bioethics Tool: Application ...........................................................................250
Recommended publications
  • Coronavirus: Covid-19 Has Killed More People Than SARS and MERS Combined, Despite Lower Case Fatality Rate

    Coronavirus: Covid-19 Has Killed More People Than SARS and MERS Combined, Despite Lower Case Fatality Rate

    BMJ 2020;368:m641 doi: 10.1136/bmj.m641 (Published 18 February 2020) Page 1 of 1 News BMJ: first published as 10.1136/bmj.m641 on 18 February 2020. Downloaded from NEWS Coronavirus: covid-19 has killed more people than SARS and MERS combined, despite lower case fatality rate Elisabeth Mahase The BMJ The novel coronavirus that has so far spread from China to 26 This comment came after the first case of covid-19 was countries around the world does not seem to be as “deadly as confirmed in Africa (in Egypt). Commenting on this milestone other coronaviruses including SARS and MERS,” the World in the outbreak, Trudie Lang, director of the Global Health Health Organization has said. Network at the University of Oxford, said it was “important but At a briefing on 17 February WHO’s director general, Tedros not unexpected.” She highlighted the fact that WHO had Adhanom Ghebreyesus, said that more than 80% of patients declared the outbreak a “public health emergency” to “support with covid-19 have a “mild disease and will recover” and that less well resourced nations in responding and preparing for it is fatal in 2% of reported cases. In comparison, the 2003 cases.” outbreak of severe acute respiratory syndrome (SARS) had a Lang praised the response of the Africa Centres for Disease case fatality rate of around 10% (8098 cases and 774 deaths), Control and Prevention, which is based in Ethiopia and supports http://www.bmj.com/ while Middle East respiratory syndrome (MERS) killed 34% countries with surveillance, emergency responses, and of people with the illness between 2012 and 2019 (2494 cases prevention of infectious disease.
  • Annual Meeting

    Annual Meeting

    Volume 97 | Number 5 Volume VOLUME 97 NOVEMBER 2017 NUMBER 5 SUPPLEMENT SIXTY-SIXTH ANNUAL MEETING November 5–9, 2017 The Baltimore Convention Center | Baltimore, Maryland USA The American Journal of Tropical Medicine and Hygiene The American Journal of Tropical astmh.org ajtmh.org #TropMed17 Supplement to The American Journal of Tropical Medicine and Hygiene ASTMH FP Cover 17.indd 1-3 10/11/17 1:48 PM Welcome to TropMed17, our yearly assembly for stimulating research, clinical advances, special lectures, guests and bonus events. Our keynote speaker this year is Dr. Paul Farmer, Co-founder and Chief Strategist of Partners In Health (PIH). In addition, Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases, will deliver a plenary session Thursday, November 9. Other highlighted speakers include Dr. Scott O’Neill, who will deliver the Fred L. Soper Lecture; Dr. Claudio F. Lanata, the Vincenzo Marcolongo Memorial Lecture; and Dr. Jane Cardosa, the Commemorative Fund Lecture. We are pleased to announce that this year’s offerings extend beyond communicating top-rated science to direct service to the global community and a number of novel events: • Get a Shot. Give a Shot.® Through Walgreens’ Get a Shot. Give a Shot.® campaign, you can not only receive your free flu shot, but also provide a lifesaving vaccine to a child in need via the UN Foundation’s Shot@Life campaign. • Under the Net. Walk in the shoes of a young girl living in a refugee camp through the virtual reality experience presented by UN Foundation’s Nothing But Nets campaign.
  • The Pharma Barons: Corporate Law's Dangerous New Race to the Bottom in the Pharmaceutical Industry

    The Pharma Barons: Corporate Law's Dangerous New Race to the Bottom in the Pharmaceutical Industry

    Michigan Business & Entrepreneurial Law Review Volume 8 Issue 1 2018 The Pharma Barons: Corporate Law's Dangerous New Race to the Bottom in the Pharmaceutical Industry Eugene McCarthy University of Illinois Follow this and additional works at: https://repository.law.umich.edu/mbelr Part of the Business Organizations Law Commons, Consumer Protection Law Commons, Food and Drug Law Commons, and the Rule of Law Commons Recommended Citation Eugene McCarthy, The Pharma Barons: Corporate Law's Dangerous New Race to the Bottom in the Pharmaceutical Industry, 8 MICH. BUS. & ENTREPRENEURIAL L. REV. 29 (2018). Available at: https://repository.law.umich.edu/mbelr/vol8/iss1/3 This Article is brought to you for free and open access by the Journals at University of Michigan Law School Scholarship Repository. It has been accepted for inclusion in Michigan Business & Entrepreneurial Law Review by an authorized editor of University of Michigan Law School Scholarship Repository. For more information, please contact [email protected]. THE PHARMA BARONS: CORPORATE LAW’S DANGEROUS NEW RACE TO THE BOTTOM IN THE PHARMACEUTICAL INDUSTRY Eugene McCarthy* INTRODUCTION......................................................................................... 29 I. THE RACE TO THE BOTTOM AND THE RISE OF THE ROBBER BARONS ..................................................................................... 32 A. Revising the Corporate Codes............................................ 32 B. The Emergence of Nineteenth-Century Lobbying ............. 37 C. The Robber
  • Written Evidence Submitted by the BBC

    Written Evidence Submitted by the BBC

    Written evidence submitted by the BBC The DCMS Sub-committee on Online Harms and Disinformation Covid-19 Inquiry April 2020 Executive summary 1. The BBC is the leading public service broadcaster in the UK, with a mission to inform, educate and entertain. Our first public purpose is to provide impartial news and information to help people understand and engage with the world around them, and we deliver this across national, local and global news services.1 2. The Editorial Guidelines are the standards that underpin all our journalism, at all times, including during the Covid-19 pandemic. They apply to all our content, wherever and however it is received. Producing and upholding these Editorial Guidelines is an obligation across the BBC and all output made in accordance with these Editorial Guidelines fulfills our public purposes and meets and goes beyond the requirements of our regulator, Ofcom. 3. Coverage of Covid-19 is dominating the UK news across all platforms. And with a plethora of cross platform content, people are most likely to turn to the BBC’s TV, radio and online services for the latest news on the pandemic (82%)2, significantly more than any other source. 4. BBC News has attracted record audiences across platforms with our nations and regions, UK wide and international coverage highlighting the importance of impartial and accurate news at this time. 5. The BBC remains the UK’s primary source for news. In a world of fake news and disinformation online, audiences said they turn to the BBC for a reliable take on events and this reputation for accuracy and trust sends audiences to the BBC during breaking news and to verify facts.3 During the Covid-19 pandemic 83% of people trust coverage on BBC TV4; and audiences from the UK and around the world have come to BBC News in their millions to stay informed and seek trusted advice on how they can protect themselves and those most at risk.
  • Transparency in the Time of Constant Change

    Transparency in the Time of Constant Change

    PhUSE 2014 Paper RG02 Transparency in the Time of Constant Change Todd Case, Biogen Idec, Cambridge MA, USA ABSTRACT The time has come, after years of hard work, to submit your application to the regulatory agency for review and possible approval! What a relief to be able to finally hand off all of your hard work and, wait a minute, ensure that all data can be reproducible?!? While CDISC has been widely adopted and its SDTM and AdAM models widely implemented, there is still the need to understand the process of ensuring that all the data is a reflection of how it was originally collected, which in some cases can be very challenging. This paper will discuss some more trending ways of both creating and presenting data in ways that ensure it is consumable and can be understood not only for analysis/submission purposes but also that post-approval it is transparent and that everyone who has a vested stake can review the data in an appropriate way. INTRODUCTION With the publication of Bad Pharma: How Medicine is Broken , and How We Can Fix it, by Dr. Ben Goldacre in 2013 a bright spotlight was shone on the data behind/supporting clinical trials. A large part of his thesis is that pharmaceutical companies exaggerate the efficacy of successful trials and that, in addition to drug companies, regulators , physicians (who are educated by the drug companies) and even patient groups have failed to protect us. Another rather striking revelation was that a clinical trial with positive results is twice more likely to be published than one with negative results (although it should be noted that this specifically is related to results – the protocol is always provided).
  • Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients by Ben Goldacre

    Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients by Ben Goldacre

    RCSIsmjbook review Bad Pharma: How drug companies mislead doctors and harm patients by Ben Goldacre Reviewed by Eoin Kelleher, RCSI medical student Paperback: 448 pages Publisher: Fourth Estate, London Published 2012 ISBN: 978-0-00-735074-2 Dr Ben Goldacre earned his reputation for his 2008 book Bad to affect doctors’ prescribing habits (although most doctors claim Science and his column in the Guardian newspaper of the same that their own practices have never been affected, just those of their name. In both he provides an entertaining, accessible and colleagues). Even journals, which are considered to be an unbiased well-researched exposé of poor scientific practices. Compared to source of medical knowledge, are not free from this – journal articles his first book, which played charlatans such as Gillian McKeith are regularly ghost-written by employees of drug companies and an and homoeopathists for laughs, Bad Pharma is a much more eminent academic is invited to put their name to it; this appears in sombre read. However, as a piece of investigative journalism, and the journal, again without disclosure. a resource for students, doctors and patients, it is invaluable. Drugs are tested by the people who Food for thought Goldacre opens by making a claim that: “Drugs are tested by the manufacture them, in poorly designed people who manufacture them, in poorly designed trials, on trials, on hopelessly small numbers of hopelessly small numbers of weird, unrepresentative patients, and unrepresentative patients, and analysed analysed using techniques which are flawed by design, in such a way that exaggerate the benefits of treatments.
  • Drugs, Money and Misleading Evidence

    Drugs, Money and Misleading Evidence

    Books & arts tallying up the inequalities. She recruited colleagues to gather much more data. The culmination was a landmark 1999 study on gender bias in MIT’s school of science (see go.nature.com/2ngyiyd), which reverber- ated across US higher education and forced many administrators to confront entrenched discrimination. Yet Hopkins would rather have spent that time doing science, she relates. The third story comes from Jane Willenbring, a geoscientist who in 2016 filed a formal com- plaint accusing her PhD adviser, David March- ant, of routinely abusing her during fieldwork in Antarctica years before. Marchant, who has denied the allegations, was sacked from his post at Boston University in April 2019 after an inves- tigation. Picture a Scientist brings Willenbring together with Adam Lewis, who was also a grad- uate student during that Antarctic field season and witnessed many of the events. Their conver- sations are a stark reminder of how quickly and how shockingly the filters that should govern work interactions can drop off, especially in UPRISING, LLC Biologist Nancy Hopkins campaigned for equal treatment at work for female scientists. remote environments. Lewis tells Willenbring he didn’t realize at the time that she had been as they admit on camera. scientists. Its two other protagonists are white bothered, because she did not show it. “A ton The iceberg analogy for sexual harassment is women with their own compelling stories. of feathers is still a ton,” she says. apt. It holds that only a fraction of harassment — Biologist Nancy Hopkins was shocked In stark contrast, the film shows us obvious things such as sexual assault and sex- when Francis Crick once put his hands on Willenbring, now at the Scripps Institution of ual coercion — rises into public consciousness her breasts as she worked in the laboratory.
  • Agenda, WHO Ebola Research and Development Summit

    Agenda, WHO Ebola Research and Development Summit

    WHO Ebola Research and Development Summit Geneva, 11 – 12 May 2015 WHO Executive Board Room Agenda Rapporteur: Elisabeth Heseltine Monday 11 May 2015 8:00-9:00 Registration Session 1: Introduction Chair: John Mackenzie (Curtin University, Australia) 9:00-9:15 Welcome: Margaret Chan, Director-General, World Health Organization (WHO) and Objectives of meeting, expected outcomes: Marie-Paule Kieny, Assistant-Director General, Health Systems and Innovation (WHO) 9:15-9:35 Keynote lecture: The Ebola response/getting to zero (20 min), Bruce Aylward (WHO) 9:35-10:15 Country perspectives on R&D during the Ebola epidemic (10 min each) • Wiltshire Johnson (Pharmacy Board, Sierra Leone) • Stephen Kennedy (Ministry of Health, Liberia) • Mandy Kader Konde (CEFORPAG, Guinea) Discussion (10 min) 10:15-10:45 Coffee break SESSION 2: Main lessons learnt on R&D in the 2014-15 EVD outbreak in West Africa. Main challenges, and factors that facilitated implementation of research activities in the affected countries Chair: Nicole Lurie (HHS/ASPR, USA) 10:45-11:30 What were the known facts, pipelines and major challenges to Ebola R&D when the international emergency was declared in August 2014, and what has been achieved since then? This presentation and discussion will identify crucial knowledge gaps at the start of the outbreak, e.g., in immunopathogenesis, appropriate animal models, use of in vitro data, natural history of disease ; and map out the current (May 2015) achievements in filling these gaps. Peter Jahrling (NIH/NIAID, USA): Addressing knowledge
  • “The Hidden Manipulation: the Influence of Pharmaceutical Companies on Physicians and Researchers” by Shivankar Vajinepalli

    “The Hidden Manipulation: the Influence of Pharmaceutical Companies on Physicians and Researchers” by Shivankar Vajinepalli

    “The Hidden Manipulation: The Influence of Pharmaceutical Companies on Physicians and Researchers” By Shivankar Vajinepalli The Undergraduate Research Writing Conference • 2020 • Rutgers, The State University of New Jersey The Hidden Manipulation: The Influence of Pharmaceutical Companies on Physicians and Researchers Shivankar Vajinepalli Professor Kathleen Wilford Research in Disciplines: Science, Medicine, and Society 2 May 2019 Vajinepalli 1 Abstract Pharmaceutical companies spend a significant amount of money on physician advertising and industry sponsored research. Involvement from pharmaceutical companies in these areas can divert the focus away from patient safety and causes changes in prescribing behavior and can cause the “funding effect.” Therefore, it can be concluded that industry involvement in research and physician marketing does negatively impact patient safety, and the relationship between physicians, researchers and the industry should not be eliminated, but more strictly regulated. When physicians are visited by pharmaceutical sales representatives (PSR), their prescribing habits are negatively affected. PSRs also do not provide accurate information to physicians about medications, and therefore physician advertising should be more strictly regulated to protect patients. Possible solutions such as providing federally funded PSRs and licensing PSRs to improve the quality of information they provide should be implemented not to eliminate, but to control physician advertising. Industry presence in research causes bias in designing and publishing research studies. The funding effect causes industry funded research to report greater benefits and safety of the medications being studied. Bias in research and lack of laws regulating disclosures of conflicts of interests also raise questions about the authenticity of studies published in medical journals. Since research cannot continue without the funding from pharmaceutical companies, they should continue to fund research, but strict ethical regulations should be followed.
  • Presentation

    Presentation

    ISSUE PANEL 1: PRAGMATIC CLINICAL TRIALS TO ESTIMATE TREATMENT EFFECTS: ARE THEY WORTH THE EFFORT? Presented by the ISPOR Statistical Methods in HEOR Special Interest Group Monday, 6 November 2017 Panelists . Rita M. Kristy, MS, Senior Director, Medical Affairs Statistics, Astellas Pharma Global Development, Northbrook, IL, USA . Helene Karcher, PhD, Managing Vice-President, Analytica Laser, Basel, Switzerland . Christoph Gerlinger, PD, Dr, Senior Director, Pharmaceuticals Statistics, Bayer AG, Berlin, and Gynecology and Obstetrics, University of Saarland, Homburg, Germany . Keith R. Abrams, PhD, CStat, Professor of Medical Statistics, NIHR Senior Investigator Emeritus & Head, Biostatistics Research Group, Department of Health Sciences, University of Leicester, Leicester, UK 2 1 What is a pragmatic clinical trial? . Can this intervention work under ideal conditions (explanatory) vs. Does the intervention work under usual conditions (pragmatic) 3 PRECIS-2 Criteria . Pragmatic-Explanatory Continuum Indicator Summary 2 . Developed and validated to improve issues with the original PRECIS . 9 domains scored from very explanatory to very pragmatic 4 2 PRECIS-2 Wheel The PRagmatic-Explanatory Continuum Indicator Summary 2 (PRECIS-2) wheel. Adapted from BMJ 2015;350:h2147 5 Examples of PRECIS-2 wheel Little P, Moore M, Kelly J, Williamson I, Leydon G, McDermmott L, Mullee M, Stuart B: Ibuprofen, paracetamol, and steam for patients with respiratory tract infections in primary care: pragmatic randomised factorial trial. BMJ 2013, 347:f6041. 6 3
  • Wet News Water Special Interest Group Newsletter

    Wet News Water Special Interest Group Newsletter

    Wet News Water Special Interest Group Newsletter Issue 81, May 2020 WATER SPECIAL INTEREST GROUP Water Water Special Interest Group Special Interest Group News from the IChemE Water Special Interest Group Wet News Water Special Interest Group Newsletter Issue 81, May 2020 Editor: Paul Curtis, email: [email protected] or [email protected] Contents Editorial 1 Backwashings 1 From the Chair - Composting Toilets & Everything the Water Industry is doing on Covid-19 2 Secretary's Report 5 AGM 6 Unflushables 2030? Mapping Change Points for Intervention for Sewer Blockages: Workshop Proceedings 27 & 28 January 2020 6 European Biosolids & Organic Resources Conference & Exhibition, 19 & 20 November 2019 8 Water & Sustainability 9 Wanted: Book Reviewers 9 WATER SPECIAL INTEREST GROUP C0490_17 www.icheme.org/water Water Water Special Interest Group Special Interest Group EDITORIAL I turn on my computer and try to remember what day it is, as one day seems to merge into another – always the same home environment but with different calls on Skype, Teams or conference calls. Sometimes I get a moment from the incessant meetings to catch up on emails or important tasks such as editing this newsletter! The world is in turmoil and the challenges of COVID-19 affect how we, at the @one Alliance (Anglian Water’s Capital Delivery Team) engage with site teams, operations teams and managing a design team working from home, whilst managing home schooling and all the usual demands of life! Little different, I am sure, from most of our readers…….the Summer weather is enticing and looking out the window I see signs of things returning to some sort of normality.
  • RESEARCH and DEVELOPMENT GOALS for COVID-19 in AFRICA the African Academy of Sciences Priority Setting Exercise CONTENTS

    RESEARCH and DEVELOPMENT GOALS for COVID-19 in AFRICA the African Academy of Sciences Priority Setting Exercise CONTENTS

    UPDATE – RESEARCH AND DEVELOPMENT GOALS FOR COVID-19 IN AFRICA The African Academy of Sciences Priority Setting Exercise CONTENTS Introduction ...............................................................................................................................................................3 Aim ............................................................................................................................................................................4 Methods ....................................................................................................................................................................5 Data Analysis .............................................................................................................................................................6 Results ......................................................................................................................................................................7 A. Quantitative Data ..............................................................................................................................................7 1. Virus natural history, transmission and diagnostics .......................................................................................................... 8 2. Animal and environmental research on the virus origin, and management measures at the human-animal interface ........ 9 3. Epidemiology studies ...................................................................................................................................................